



PRESS RELEASE 2022-11-21

SelectImmune Pharma holds a digital investor meeting

SelectImmune Pharma is inviting you to a digital investors' meeting via Zoom, on Tuesday November 29th at 12.00 CET, for dialogue and to follow up from the General meeting. We welcome existing owners, other investors and interested parties to join. The meeting participants will be informed of the company developments and will be invited to ask questions. These may be asked online during the meeting or be sent via e-mail to the addresses listed below. Please use this link to participate:

<https://us06web.zoom.us/j/84640256743?pwd=dDFtNEVJWtJBaVV4ZGp3K3pZWkFBdz09>

Meeting ID: 846 4025 6743

Passcode: 108328

For written questions, please contact:

Gabriela Godaly
CEO (acting), SelectImmune Pharma AB
Tel: +46 733 38 13 44
E-mail: gabriela.godaly@selectimmune.com

Catharina Svanborg
Chairman SelectImmune Pharma AB
Tel: +46 709 42 65 49
E-mail: catharina.svanborg@med.lu.se

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company develops new immunotherapies, which act as immune modulators and offer complements to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can

supplement or replace antibiotics. Urinary tract infections (UTI) are extremely common, affecting at least 50% of all women. There is an immediate need for treatment alternatives and the potential markets are very large.